StockData
GRI Bio, Inc. logo

GRI Bio, Inc. (GRI) stock

GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.35−0.05 (-3.54%)

Close on Nov 17, 2026Market cap $2.95MP/E –Yield –

GRI Bio r&d expenses

Research and development expenses are spending on new products and technology.

GRI Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.17M, down 24.9% year over year. For fiscal 2025 it was $6.82M, up 81.0% from the year before. The highest annual figure on record is $6.82M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.82M+81.0%
FY2024Dec 31, 2024$3.77M+16.6%
FY2023Dec 31, 2023$3.23M+1235.5%
FY2022Dec 31, 2022$242.00K-95.3%
FY2021Dec 31, 2021$5.19M+39.9%
FY2020Dec 31, 2020$3.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$407.00K-78.3%
Q1 FY2026Mar 31, 2026$361.00K-78.0%
Q4 FY2025Dec 31, 2025$1.63M+79.8%
Q3 FY2025Sep 30, 2025$1.77M+57.2%
Q2 FY2025Jun 30, 2025$1.88M+114.3%
Q1 FY2025Mar 31, 2025$1.64M+75.8%
Q4 FY2024Dec 31, 2024$907.00K-13.3%
Q3 FY2024Sep 30, 2024$1.13M-5.4%
Q2 FY2024Jun 30, 2024$877.00K-0.3%
Q1 FY2024Mar 31, 2024$933.00K+704.3%
Q4 FY2023Dec 31, 2023$1.05M+1614.8%
Q3 FY2023Sep 30, 2023$1.19M+1787.3%
Q2 FY2023Jun 30, 2023$880.00K+1391.5%
Q1 FY2023Mar 31, 2023$116.00K-90.9%
Q4 FY2022Dec 31, 2022$61.00K-96.9%
Q3 FY2022Sep 30, 2022$63.00K-70.7%
Q2 FY2022Jun 30, 2022$59.00K-95.1%
Q1 FY2022Mar 31, 2022$1.27M-28.3%
Q4 FY2021Dec 31, 2021$2.00M+56.1%
Q3 FY2021Sep 30, 2021$215.00K-70.7%
Q2 FY2021Jun 30, 2021$1.20M+48.8%
Q1 FY2021Mar 31, 2021$1.77M+100.7%
Q4 FY2020Dec 31, 2020$1.28M–
Q3 FY2020Sep 30, 2020$733.00K–
Q2 FY2020Jun 30, 2020$808.00K–
Q1 FY2020Mar 31, 2020$883.00K–

More GRI Bio figures

See a number that looks wrong?